Insilico Medicine
Generative AI platform for end-to-end drug discovery, from target identification to clinical trials
Enterprise·Technical·Powered by Insilico Medicine (proprietary LLLMs)·API available
Key strengths
End-to-end AI-driven drug discovery pipeline (target ID to clinical trials)Generative chemistry and biology AI (Chemistry42, Generative Biologics)Large Language of Life Models (LLLMs) for biomedical researchValidated therapeutic pipeline with programs in Phase I/II trialsMulti-modal platform covering disease modeling, molecule generation, and clinical prediction
Enterprise pricing
Cambridge, USA
Founded 2014
No ratings yet
Technical Integration & Developer Reference
Platform Modules
| Module | Function | Key Technology |
|---|---|---|
| PandaOmics | Multi-omics target discovery & disease modeling | Graph neural networks, multi-omics data fusion |
| Chemistry42 | Generative small molecule design & optimization | Reinforcement learning, generative adversarial networks |
| Generative Biologics | AI-designed biologic therapeutics | Protein language models, structure prediction |
| inClinico | Clinical trial success prediction | Transformer-based outcome models |
| Science42:DORA | LLM research assistant | Large Language of Life Models (LLLMs) |
Licensing & API Access
- Platform modules are available for enterprise licensing; contact Insilico for API credentials and integration documentation.
- Benchmarks and evaluation datasets are published at Insilico Bench and the Drug Discovery Benchmark for reproducible third-party validation.
MMAI Gym
- Provides standardized environments and benchmarks for training and evaluating AI models in drug discovery contexts, enabling researchers to compare methods against Insilico's published results.
Security & Compliance
- Insilico maintains dedicated Security & IT governance documented on their site; enterprise deployments include data privacy controls suitable for proprietary compound libraries and clinical data.